Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 vaccine response in rheumatoid arthritis patients treated with rituximab
NL-OMON28096Active, not recruiting
- Sponsor
- Sint Maartenskliniek
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of rituximab in coronavirus disease 2019 (COVID-19) and rheumatoid arthritis (RA) (3 cohorts), sponsored by Sint Maartenskliniek. Primary endpoints: Humoral response 2-6 weeks after last vaccine dose and Humoral response 2-6 weeks after third vaccine dose. Started Mar 2021; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
coronavirus disease 2019 (COVID-19)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON28096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28096.